In October 2009, pazopanib (Votrient; GlaxoSmithKline) — a multikinase inhibitor with targets that include vascular endothelial growth factor receptors — was approved by the US FDA for the treatment of advanced renal cell carcinoma.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Garcia, J. A. & Rini, B. I. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J. Clin. 57, 112–125 (2007).
Atkins, M. A. et al. Everolimus. Nature Rev. Drug Discov. 8, 535–536 (2009).
Heng, D. Y. & Bukowski, R. M. Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. Curr. Cancer Drug Targets 8, 676–682 (2008).
Harris, P. A. et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J. Med. Chem. 51, 4632–4640 (2008).
Kumar, R. et al. Pharmacokinetic–pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther. 6, 2012–2021 (2007).
Food and Drug Administration. FDA labelling information. FDA website [online], (2009).
Sternberg, C. N. et al. A randomized, double-blind phase lll study of pazopanib in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol. 27, 15s A5021 (2009).
Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).
Motzer, R. J. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516–2524, (2006).
Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 372, 449–456 (2008).
IMS MIDAS (IMS Health, 2009).
SG Cowen Research Team. SG Cowen Therapeutic Categories Outlook (Sep 2009).
Hauber, A., Vosser, R. & Evans, D. JP Morgan Equity Research Report (11 Sep 2009).
R.M.B. has received honoraria and acted as a consultant for Pfizer, Novartis and Genentech, and has acted as a consultant for GSK and Bayer.
About this article
Abnormal Crosstalk between Endothelial Cells and Podocytes Mediates Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity
Nature Reviews Drug Discovery (2021)
Development, synthesis, and biological evaluation of sulfonyl‐α‐ l ‐amino acids as potential anti‐ Helicobacter pylori and IMPDH inhibitors
Archiv der Pharmazie (2021)
A Palladium-Catalyzed Domino Reaction To Access 3-Amino-2H-indazoles from Hydrazines and 2-Halobenzonitriles
Organic Letters (2020)